Damon Runyon Cancer Research Foundation awards $3.3 million ... EurekAlert (press release) Despite the promising activity of antibodies such as rituximab (Rituxan, targets CD20), trastuzumab (Herceptin, targets HER2), and cetuximab (Erbitux, targets ... |
